Not So Evergreen
April 1, 2013 12:26 PM Subscribe
posted by vidur (15 comments total)
6 users marked this as a favorite
"India's supreme court has ruled against Swiss drug giant Novartis in a landmark case
that activists say will protect access to cheap generic drugs in developing nations."
"Glivec sells in developed nations for more than $3,000 for a month's worth of treatment, but a generic version is sold in India for less than $200."
"The Indian Patent Office in 2006 denied a patent to Novartis, a decision upheld by the Indian Intellectual Property Appellate Board. The board cited a provision of Indian law that aims to prevent “evergreening,”
in which companies make an incremental change to a drug’s chemical makeup, without any real medical benefit, to extend its patent life and prevent the introduction of low-cost generic copies."
Novartis says it will stop investing
in R&D in India.